News
![daiichi sankyo](https://pharmaphorum.com/wp-content/uploads/2018/08/daiichi-sankyo.jpg)
Lixiana hits the mark in catheter ablation trial
Daiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker hopes new data in atrial fibrillation (AFib) could accelerate its gro